Sentinel lymph node biopsy after neoadjuvant treatment of breast cancer using blue dye, radioisotope, and indocyanine gree

Phase 3

Completed

• Conditions: ocally advanced breast cancer patients; Locally advanced breast cancer patients; sentinel lymphnodes; Sentinel lymph node biopsy; indocyanine green; neoadjuvant chemotherapy

• Registration Number: TCTR20200730003
• Lead Sponsor: Department of surgery Faculty of medicine Ramathibodi Hospital , Mahidol university , Bangkok , Thai

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2020-03-31
• Study Start: 2020-07-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

Eligible patients were those with locally advanced breast cancer (T2â€4, N1â€2) who received neoadjuvant treatment, with tissue pathology confirmed carcinoma

Exclusion Criteria

Patients who had surgical biopsy or surgery that involved the axillary regions, and those with a history of allergy to ICG, isosulfan blue, or radioisotope were excluded from the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
number of sentinel lymph node biopsy using blue dye , radioisotrope , ICG 15 minutes after injection blue dye and ICG , 60 mins after inject radioisotrope Statistical analysis of patients’ characteristic data was done using descriptive statistics. The i

Secondary Outcome Measures

Name	Time	Method
accuracy of sentinel lymph node biopsy in post neoadjuvant treatment breast cance 15 minutes after injection blue dye and ICG , 60 mins after inject radioisotrope Statistical analysis of patients’ characteristic data was done using descriptive statistics. The i